Psilocybin Treatment Linked to Symptom Reduction in 19 Patients with Treatment-Resistant Depression

A study published in *The Lancet Regional Health—Europe* reports that psilocybin treatment correlates with a significant reduction in symptoms among patients suffering from treatment-resistant depression. Researchers observed 19 individuals who received the substance as part of a clinical investigation, noting measurable improvements in their mental health status following the intervention.

The clinical trial focused specifically on patients who had previously failed to respond to conventional depression therapies. By administering psilocybin in a controlled setting, the research team tracked changes in the participants’ depressive symptoms over the course of the study. The findings provide new data regarding the potential effects of the compound on persistent, treatment-resistant cases, adding to the ongoing scientific inquiry into alternative psychiatric treatments.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 2, 2026

Author

GOAI